- A rare brain autopsy study shows that the discontinued Alzheimer's drug aducanumab did not fully clear amyloid-beta plaques and tau tangles in all brain regions, potentially explaining its limited effectiveness.
- The case suggests anti-amyloid therapies may help reduce tau accumulation and slow brain atrophy in some regions, offering human evidence for the relationship between amyloid removal and neurodegeneration.
- Despite aducanumab's failure, some researchers believe targeting amyloid early could still be beneficial, but other scientists question its direct causal link to improving cognition in Alzheimer's patients.
- Recent reviews of clinical trials indicate that anti-amyloid drugs lack clinically meaningful positive effects in patients with mild cognitive impairment or mild dementia, raising doubts about the amyloid-focused approach.